Business Wire

Big Hydrogen Production Plans of Proton Technologies

Share

Proton Technologies began separating hydrogen again in late February at their project in Saskatchewan, Canada. The new separation unit is for multi-year hydrogen filter longevity and iteration testing, with hydrogen truck-loading expected later this year. Liquid oxygen is scheduled to be trucked in for injection at modest but still commercial scale. At the demonstration site production is expected to reach one thousand tonnes hydrogen per day after construction of a large air separation unit.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210310005634/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Proton Technologies Black Box at site near Kerrobert, Saskatchewan. (Photo: Business Wire)

Hydrogen is a carbonless fuel which creates no CO2 when used. Proton has a way to make clean hydrogen at an anticipated production cost below $0.30 US per kg with a lower carbon intensity than wind or solar to electrolysis. Oil fields are not abandoned because they are empty, rather they have reached an economic limit but much of the oil remains in the ground. Proton’s process involves injecting oxygen into oilfields. This triggers reactions that produce hydrogen. Then a downhole hydrogen filter only allows hydrogen to come into the production well and up to surface, leaving all carbon in the ground. The cost structure is low because late-life oilfields become Proton’s reaction vessel which already contains decades of fuel.

There are many paths to move hydrogen, by truck, by rail, by pipeline, as a gas, as a liquid, or incorporated into chemicals such as ammonia, but if the production cost of hydrogen is lower than natural gas, baseload electricity and blending into natural gas systems are attractive as large proven markets with existing infrastructure and customers. “We plan to fuel our power purchase agreement using hydrogen-compatible generators,” says Seta Afshordi, COO of Proton Canada.

A journey is more purposeful when the destination is known. “Proton Canada aspires to supply 10% of humanity’s total energy by 2040. This will require huge investment for construction of many large air separation units and about 1/10th of western Canada’s vast oil resource, most of which is uneconomic for oil production,” says Grant Strem, Chair & CEO. Enquiries may be made to investorrelations@proton.energy, careers@proton.energy, or info@proton.energy.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For Media:
Proton’s Chair & CEO Grant Strem, COO Seta Afshordi, and Head of Commercial Calvin Johnson are available for interviews. Bookings can be made through
Julie Goulder julie@proton.energy

+1 403 467 1220

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SBC Medical Group Enters the Thai Market through Partnership with BLEZ14.11.2025 14:47:00 EET | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced that it has entered into a Consulting Agreement with BLEZ ASIA Co., Ltd. (Headquarters: Bangkok, Thailand; CEO: Naoki Iida; “BLEZ”), which operates more than 20 pharmacies and clinics in Thailand and is widely trusted by both Japanese expatriates and local patients. The partnership is a key component of SBC’s broader Asia strategy and represents a significant step toward full-scale entry into the rapidly growing Thai aesthetic medicine market. Under the agreement, SBC will provide comprehensive management support to a new clinic focused primarily on dermatological treatments such as pigmentation and spot removal, which BLEZ is preparing to open in Bangkok. SBC will advise on clinical protocol development, aligned with SBC’s quality standards, and assist in selecting me

SBC Medical Group Holdings Announces Third Quarter 2025 Financial Results14.11.2025 14:00:00 EET | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced its financial results for the third quarter of fiscal year 2025 (three months ended September 30, 2025) and for the third quarter cumulative of fiscal year 2025 (Year-to-Date 2025, nine months ended September 30, 2025) Third Quarter 2025 Highlights Total revenues were $43 million, representing an 18% year-over-year decrease. Income from operations was $16 million, representing a 15% year-over-year increase. Net Income attributable to SBC Medical Group was $13 million , representing an 353% year-over-year increase. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.12 for the three months ended September 30, 2025, compared to $0.03 in the same period of 2024. EBITDA1, which

Ant Group Chairman Eric Jing Outlines Strategy for Inclusive AI, Collaboration on Tokenised Settlement14.11.2025 12:15:00 EET | Press release

Eric Jing, Chairman of Ant Group, said the company's focus is on putting new payment and operation tools powered by AI and tokenisation technology in the hands of SMEs, to fully embrace the next wave of global productivity revolution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251114239737/en/ Ant Group Chairman Eric Jing (second from right) shares insights during a panel discussion titled “Steering the Global Future” during the Singapore FinTech Festival on November 14, 2025. “We are passionate about using frontier technology to support SMEs and the use of AI will really uplift inclusion,” Jing said during a panel discussion titled “Steering the Global Future” during the Singapore FinTech Festival on November 14, 2025. Jing was joined by Agustín Carstens, Former General Manager, Bank for International Settlements (BIS); Ravi Menon, Chairman of the Board of Directors, Global Finance & Technology Network (GFTN); Ambassado

Allianz Achieves Record Results and Expects a Full-Year Operating Profit of at Least 17 Billion Euros14.11.2025 08:16:00 EET | Press release

3Q 2025 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251113803211/en/ Oliver Bäte, Chief Executive Officer of Allianz SE Double-digit growth in operating profit and shareholders’ core net incomeTotal business volume rises 5.21 percent with contributions from all segments Operating profit increases 12.6 percent to 4.4 billion euros, with particular strong contribution from the Property-Casualty segment Shareholders’ core net income advances by 12.7 percent and reaches 2.9 billion euros 9M 2025 Continued strong and diversified growth across our businessesand record operating profitTotal business volume rises 8.5 1 percent and reaches 141.2 billion euros with contributions from all segments Operating profit increases 10.4 percent to 13.1 billion euros, our highest nine-month operating profit ever, reaching 82 percent of our full-year outlook midpoint Shareholders’ core net income advances 10.5 percent to 8.4 billion euros. Ad

Galderma Completes Successful Placement of CHF 175 Million Bond14.11.2025 08:00:00 EET | Press release

NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION. Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the successful placement of a single-tranche CHF 175 million Swiss franc-denominated bond. The bond has a maturity of 5 years and carries a fixed-rate annual coupon of 0.9425%. Net proceeds from the transaction will be used to partially refinance Galderma’s existing bank term loan issued at its initial public offering (IPO) in March 2024, as well as for general corporate purposes. This marks the company’s third CHF-bond issuance since listing. The new bond will be listed on the SIX Swiss Exchange, with the settlement date expected on December 10, 2025. BNP Paribas and UBS jointly led the transaction. Galderma is rated BBB (stable outlook) by Fitch. The same rating is also expected to be assigned to the new bond. The successful issuance is leverage-ne

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye